{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:14Z","timestamp":1792521434436,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>. The Vaccine Adverse Event Reporting System (VAERS) is the United States national passive vaccine safety surveillance system. We updated the data on the safety of single-antigen varicella vaccine (VAR) and assessed the safety of combination measles, mumps, rubella, and varicella vaccine (MMRV) licensed in the United States using VAERS data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>US VAERS reports received after administration of VAR and MMRV during 2006\u20132020 were identified. Reports were analyzed by vaccine type, age, seriousness, most common adverse events (AEs), and concomitant vaccines. We reviewed medical records of selected reports of AEs of special interest and conducted empirical Bayesian data mining to identify disproportionally reported AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During 2006\u20132020, approximately 132.8 million VAR doses were distributed; 40 684 reports were received in VAERS (30.6\/100 000 doses distributed), with 4.1% classified as serious (1.3\/100 000 doses distributed). Approximately 35.5 million MMRV doses were distributed; 13 325 reports were received (37.6\/100 000 doses distributed) with 3.3% classified as serious (1.3\/100 000 doses distributed). The most common adverse health events after both VAR and MMRV were injection site reactions (31% and 27%), rash (28% and 20%), and fever (12% and 14%), respectively. Vaccination errors accounted for 23% of reports after VAR administration and 41% after MMRV administration, but \u226595% of them did not describe an adverse health event. AEs associated with evidence of vaccine strain varicella-zoster virus (vVZV) infection included meningitis, encephalitis, herpes zoster, and 6 deaths (all in immunocompromised persons with contraindications for vaccination). No new or unexpected AE was disproportionally reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No new or unexpected safety findings were detected for VAR and MMRV given as recommended, reinforcing the favorable safety profiles of these vaccines. Providers should obtain specimens for viral testing and strain-typing for serious AEs if they consider vVZV as the possible causative agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac306","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:53:15Z","timestamp":1661334795000},"page":"S431-S440","source":"Crossref","is-referenced-by-count":27,"title":["Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006\u20132020"],"prefix":"10.1093","volume":"226","author":[{"given":"Pedro L","family":"Moro","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeowon","family":"Kim","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokui","family":"Wei","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Su","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Marin","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2022102100080092400_jiac306-B1","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2022102100080092400_jiac306-B2","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac221","article-title":"Monitoring varicella vaccine impact on varicella incidence in the United States: surveillance challenges and changing epidemiology, 1995\u20132019","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100080092400_jiac306-B3","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac242","article-title":"Decline in severe varicella disease during the United States varicella vaccination program: hospitalizations and deaths, 1990\u20132019","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"2022102100080092400_jiac306-B4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"issue":"Suppl 2)","key":"2022102100080092400_jiac306-B5","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1086\/522161","article-title":"Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995\u20132005","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100080092400_jiac306-B6","doi-asserted-by":"crossref","first-page":"e20162536","DOI":"10.1542\/peds.2016-2536","article-title":"Safety of second-dose single-antigen varicella vaccine","volume":"139","author":"Su","year":"2017","journal-title":"Pediatrics"},{"key":"2022102100080092400_jiac306-B7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"issue":"Suppl 2)","key":"2022102100080092400_jiac306-B8","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: a 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100080092400_jiac306-B9","doi-asserted-by":"crossref","first-page":"ofz295","DOI":"10.1093\/ofid\/ofz295","article-title":"Varicella virus vaccine live: A 22-year review of postmarketing safety data","volume":"6","author":"Woodward","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022102100080092400_jiac306-B10","author":"Food and Drug Administration","year":"2022"},{"key":"2022102100080092400_jiac306-B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"2022102100080092400_jiac306-B12","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"key":"2022102100080092400_jiac306-B13","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)\u2014United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"2022102100080092400_jiac306-B14","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"2022102100080092400_jiac306-B15","author":"MedDRA"},{"key":"2022102100080092400_jiac306-B16","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the vaccine adverse event reporting system, (VAERS) United States, 2000\u20132013","volume":"33","author":"Hibbs","year":"2015","journal-title":"Vaccine"},{"key":"2022102100080092400_jiac306-B17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"2022102100080092400_jiac306-B18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"2022102100080092400_jiac306-B19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/hv.26200","article-title":"Fatal varicella due to the vaccine-strain varicella-zoster virus","volume":"10","author":"Leung","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2022102100080092400_jiac306-B20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciu970","article-title":"Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation","volume":"60","author":"Bhalla","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022102100080092400_jiac306-B21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s10875-015-0207-8","article-title":"Late onset hypomorphic RAG2 deficiency presentation with fatal vaccine-strain VZV infection","volume":"35","author":"Dutmer","year":"2015","journal-title":"J Clin Immunol"},{"key":"2022102100080092400_jiac306-B22","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1080\/21645515.2018.1480283","article-title":"Update on trends in varicella mortality during the varicella vaccine era-United States, 1990\u20132016","volume":"14","author":"Leung","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2022102100080092400_jiac306-B23","doi-asserted-by":"crossref","first-page":"e0199229","DOI":"10.1371\/journal.pone.0199229","article-title":"Adverse events after vaccination among HIV-positive persons, 1990\u20132016","volume":"13","author":"Su","year":"2018","journal-title":"PLoS One"},{"key":"2022102100080092400_jiac306-B24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/21645515.2014.1004034","article-title":"Letter to the editor: fatal varicella due to the vaccine-strain varicella-zoster virus","volume":"11","author":"Woo","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2022102100080092400_jiac306-B25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhin.2017.05.024","article-title":"First case of vaccine-strain varicella infection as manifestation of HIV in healthcare worker: a case report and review of the literature","volume":"97","author":"Navalkele","year":"2017","journal-title":"J Hosp Infect"},{"key":"2022102100080092400_jiac306-B26","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"2022102100080092400_jiac306-B27","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2022102100080092400_jiac306-B28","author":"Merck & Co., Inc","year":"2021"},{"key":"2022102100080092400_jiac306-B29","author":"Merck & Co., Inc","year":"2021"},{"key":"2022102100080092400_jiac306-B30","volume-title":"Manual for the surveillance of vaccine-preventable diseases","author":"Lopez"},{"key":"2022102100080092400_jiac306-B31","volume-title":"Immunization safety review: vaccinations and sudden unexpected death in infancy","author":"Institute of Medicine","year":"2003"},{"key":"2022102100080092400_jiac306-B32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"2022102100080092400_jiac306-B33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2022102100080092400_jiac306-B34","volume-title":"Preventing medication errors","author":"Institute of Medicine","year":"2007"},{"key":"2022102100080092400_jiac306-B35","first-page":"1","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2022102100080092400_jiac306-B36","doi-asserted-by":"crossref","first-page":"e20191305","DOI":"10.1542\/peds.2019-1305","article-title":"Transmission of vaccine-strain varicella-zoster virus: a systematic review","volume":"144","author":"Marin","year":"2019","journal-title":"Pediatrics"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S431\/46582547\/jiac306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S431\/46582547\/jiac306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T09:13:00Z","timestamp":1727860380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/Supplement_4\/S431\/6764812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":36,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac306","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,21]]}}}